Recent studies have shown that in ER negative breast cancer, including the HER2 and basal subtypes, the presence of tumor-infiltrating CTLs correlates with anthracycline responsiveness and prolonged patient survival compared to patients without adjuvant chemotherapy (West et al., 2011). Here, ERBB2 is linked to neoplasm.